Scalper1 News
Mylan (MYL) stock broke out Wednesday as rumors circulated on Twitter that the generic and branded drugmaker might be for sale, possibly to Teva, and as it announced three drug launches. Mylan stock rose 6.7% Wednesday to 59, briefly passing a buy point of 59.70 before easing, and Teva Pharmaceutical Industries (TEVA) gained 2.5%. Analysts were divided about the logic of Teva acquiring Mylan, a competitor in generic drugs. BMO Capital Markets Scalper1 News
Scalper1 News